Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Phathom Pharmaceuticals, Inc. (PHAT) reported a Q4 loss of $0.79 per share, which was better than the Zacks Consensus Estimate of a $0.98 loss. This is a slight improvement from the $0.80 loss per share reported a year ago.
March 06, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals reported a Q4 loss of $0.79 per share, beating the Zacks estimate of $0.98. This is a slight improvement from last year's $0.80 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to positively impact PHAT's stock price in the short term. Investors often react favorably to companies that exceed earnings expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100